Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4

Leerink Partners analyst Roanna Ruiz has maintained a Market Perform rating on Rocket Pharmaceuticals (NASDAQ: RCKT) and has reduced the price target from $7 to $4. This adjustment reflects a more cautious outlook on the company's performance.